NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
Amendment No. 5 to Schedule 13G discloses that investment vehicles affiliated with Soleus Capital and managing member Guy Levy collectively own 2,303,828 shares of NeuroPace, Inc. (NPCE), equal to 7.0 % of the 32,798,505 shares outstanding on 05-09-25.
Key holders: (1) Soleus Capital Master Fund, L.P. – 1,993,507 shares (6.1 %); (2) Soleus Private Equity Fund I, L.P. – 310,321 shares (0.9 %). All entities report shared voting and dispositive power and zero sole voting/dispositive power. The filing, made 08-05-25 for an event on 06-30-25, is submitted under Rule 13d-1(c), indicating a passive investment with no intent to influence control.
The updated 7 % stake places Soleus Capital among NPCE’s largest shareholders, giving it material but not controlling influence; no financial results or transaction terms accompany the disclosure.
NeuroPace CFO Patrick F. Williams received significant equity compensation on June 20, 2025, consisting of two main components:
Restricted Stock Units (RSUs):
- 51,850 RSUs granted at $0 cost
- Vesting schedule: 25% vests on June 20, 2026, remaining vests quarterly over 3 years
Stock Options:
- 87,950 options granted with strike price of $10.41
- 10-year term, expiring June 19, 2035
- Same vesting schedule as RSUs: 25% after one year, then quarterly over 3 years
This compensation package demonstrates NeuroPace's strategy to align executive interests with long-term shareholder value through equity incentives with extended vesting periods.
NeuroPace, Inc. (NPCE) – Form 3 Initial Statement of Beneficial Ownership
Chief Financial Officer Patrick F. Williams filed an initial Form 3 for an event dated 06/20/2025. The document confirms that he currently holds no beneficial ownership—neither common stock nor derivative securities—in NeuroPace. The filing was signed by attorney-in-fact Leah Akin on 06/24/2025.
Form 3 is required when an individual becomes a Section 16 insider (director, officer, or >10 % shareholder). This submission fulfills that requirement and sets Williams’s baseline ownership level for future insider transaction reporting.
On 24 June 2025, NeuroPace (NPCE) filed a Form 4 for director Dr. Uri Geiger detailing a series of stock grants received as part of the company’s non-employee director compensation policy, issued in lieu of cash retainers.
- Latest grant: 1,140 shares on 21 June 2025 at $10.41.
- Cumulative direct holdings: 12,036 common shares after the reported transactions.
- Grant history: Eight quarterly issuances from 30 June 2023 through 21 June 2025, priced between $4.49 and $13.20, all coded “A” (acquisition).
- Indirect holdings: 4,432,948 shares held through Accelmed Partners II LP, over which Dr. Geiger exercises sole voting and dispositive control.
No shares were sold, and there are no derivative security movements disclosed. The filing is administrative, reflecting routine equity compensation rather than a strategic insider transaction.
NeuroPace director Rakhi Kumar reported multiple acquisitions of common stock between June 2023 and June 2025, received as compensation under the company's non-employee director compensation policy in lieu of quarterly retainer fees.
Key transaction details:
- Total shares accumulated: 15,594 shares
- Purchase prices ranged from $4.49 to $13.20 per share
- Largest single acquisition: 3,340 shares on June 30, 2023
- Most recent acquisition: 1,440 shares at $10.41 on June 21, 2025
All transactions were direct acquisitions, with shares held in direct ownership. The consistent pattern of quarterly acquisitions suggests regular board compensation practices, with share quantities varying based on the prevailing stock price at each grant date.
Joseph Lacob, Director at NeuroPace, reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025.
Key transactions include:
- Nine separate acquisitions totaling 11,696 shares at prices ranging from $4.49 to $13.20
- Most recent acquisition: 1,080 shares at $10.41 on June 21, 2025
- Current direct ownership: 12,080 shares
- Significant indirect ownership through: - Lacob Ventures LLC: 128,174 shares - LCT18 Investments: 223,554 shares
Total beneficial ownership (direct and indirect) amounts to 363,808 shares, demonstrating substantial insider stake in the company. All direct acquisitions were made as compensation for board service rather than open market purchases.
NeuroPace director Frank M. Fischer reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025. Key transactions include:
- Most recent acquisition: 2,281 shares at $10.41 per share on June 21, 2025
- Largest acquisition: 4,469 shares at $4.49 per share on June 30, 2023
- Total shares accumulated: Increased position from 570,126 to 589,531 shares
- Share price range: $4.49 to $13.20 across nine quarterly acquisitions
All transactions were direct ownership acquisitions, with no derivative securities involved. The consistent pattern of stock acquisitions in lieu of cash compensation demonstrates the director's long-term alignment with shareholder interests and confidence in the company's future.